Market research
TPTX Turning Point Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 71.5
- Dividend yield
- 0.0%
- Beta
- -0.19
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US90041T1088
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 71.5
- Dividend yield
- 0.0%
- Beta
- -0.19
About
About Turning Point Therapeutics Inc
Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California. As of August 15, 2022, Turning Point Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the TPTX discussion.
5 years, 4 months ago
Turning Point Therapeutics, Inc is currently in a long term downtrend where the price is trading 27.0% below its 200 day moving average.
From a valuation standpoint, the stock is 89.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 147.0.
Turning Point Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 126.0% to $-47M since the same quarter in the previous year.
Finally, its free cash flow fell by 127.6% to $-34M since the same quarter in the previous year.
Based on the above factors, Turning Point Therapeutics, Inc gets an overall score of 1/5.